Adherence to therapy: Challenges in HCV-infected patients

Current Hepatitis Reports

Volumn 6, Issue 4, 2007, Pages 160-168

  Pozza, Renee ^a   Barakat, Fatma ^b  

^a Southern California Liver Centers   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN;

COMORBIDITY; DEPRESSION; HEALTH CARE COST; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; PATIENT ATTITUDE; PATIENT COMPLIANCE; REVIEW; STIGMA; STRESS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 37049038836     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-007-0019-2     Document Type: Review

References (70)

1. • McHutchison J, Manns M, Patel K, et al.: Adherence to combination therapy enhances sustained response in genotype 1 infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061-1069. Retrospective analysis of the key clinical drug trials in HCV combination therapy to evaluate medication adherence rates and impact on virologie response. Data supported current recommendations for greater than 80% medication adherence for more than 80% of treatment duration.
2. National Institutes of Health Consensus Development Conference: Management of hepatitis C: 2002. Available at http://consensus.nih.gov/2002/ 2002HepatitisC2002116main.htm. Accessed April 2007.
3. Haynes R: Compliance in Health Care. Baltimore, MD: Johns Hopkins University; 1979.
4. Jani A: Adherence to HIV treatment regimens: recommendations for best practices. Available at http://www.apha.org/NR/rdonlyres/946B5021-79F3-4298- 94FA-A6093B43C2FC/0/4183APHABestPracAdhOverview.pdf. Accessed September 2007.
5. Christensen A: Patient Adherence to Medical Treatment Regimens: Bridging the Gap between Behavioral Science and Biomedicine. New Haven, CT: Yale University Press; 2004.
6. Dunbar-Jacob J, Foley S: An historical overview of medication adherence. In Methodological Issues in the Study of Adherence. Edited by Dunbar-Jacob J, Erlen J, Schlenk E, Stilley C. Pittsburgh, PA: Centers for Research in Chronic Disorders, School of Nursing; 2005.
7. Dunbar-Jacob J, Erlen J, Schlenk E, et al.: Adherence in chronic disease. Annu Rev Nurs Res 2000, 18:48-90.
8. Haynes R, McDonald H, Garg A.: Helping patients follow prescribed treatment: clinical applications. JAMA 2002, 288:2880-2883.
9. Ickovics J, Meisler A: Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol 1997, 50:385-391.
10. Patel K, McHutchison J: Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. Cleve Clin J Med 2004, 71(Suppl 3):S8-S12.
11. • Reynolds N: Adherence to antiretroviral therapies: state of the Science. Curr HIV Res 2004, 2:207-214. State-of-the-science article summarizing adherence literature for antirerroviral therapy (ART) in HIV. The article presents a good overview of measurements of adherence, predictors, and interventional trials in adherence to ART.
12. Simoni JM, Frick PA, Pantalone DW, Turner BJ: Anti-retroviral adherence interventions: a review of current literature and ongoing studies. Top HIV Med 2003, 11:185-198.
13. Fogarty L, Roter D, Larson S, et al.: Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns 2002, 46:93-108.
14. Chesnev M: Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000, 30:S171-S176.
15. Gifford A, Bormann J, Shively M, et al.: Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000, 23:386-395.
16. Kleeberger C, Phair J, Strathdee S, et al.: Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2001, 26:82-92.
17. Reynolds N: The problem of antiretroviral adherence: a self-regulatory model for intervention. AIDS Care 2003, 15:117-124.
18. Fisher J, Fisher W: The information-motivation-behavioral skills model of AIDS risk behavior change: empirical support and application. In Understanding and Preventing HIV Risk Behavior: Safer Sex and Drug Use. Edited by Oskamp S. Thousand Oaks, CA: Sage Publications; 1996:100-127.
19. Dunbar-Jacob J, Burke L, Puczynski S: Clinical assessment and management of adherence to medical regimens. In Managing Chronic Illness. Edited by Nicassio PM, Smith TW. Washington, DC: American Psychological Association; 1995.
20. Chesney M, Ickovics J, Hecht F, et al.: Adherence: a necessity for successful HIV combination therapy. AIDS 1999, 13:S271-S278.
21. Hauser P: Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression. Gastroenterol Clin North Am 2004, 33:S37-S50.
22. Zdilar D, Franco-Bronson K, Buchler N, et al.: Hepatitis C, interferon alfa, and depression. Hepatology 2000, 31:1207-1211.
23. Castera L, Constant A, Henry C, et al.: Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Aliment Pharmacol Ther 2006, 24:1223-1230.
24. Chainuvati S, Khalid S, Kancir S, et al.: Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders. J Viral Hepat 2006, 13:235-241.
25. Knott A, Dieperink E, Willenbring M, et al.: Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006, 101:2254-2262.
26. Rifai M, Indest D, Loftis J, et al.: Psychiatric management of the hepatitis C patient. Curr Treat Options Gastroenterol 2006, 9:508-519.
27. Angelino A, Treisman G: Evidence-informed assessment and treatment of depression in HCV and interferon-treated patients. Int Rev Psychiatry 2005, 17:471-476.
28. Golin C, Liu H, Hays R, et al.: A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002, 17:756-765.
29. Sylvestre D: Treating hepatitis C virus infection in active substance users. Clin Infect Dis 2005, 40:S321-S324.
30. Sylvestre D, Loftis J, Hauser P, et al.: Co-occurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health 2004, 81:719-734.
31. Taylor L: Delivering care to injection drug users coinfected with HIV and hepatitis C virus. Clin Infect Dis 2005, 40:S355-S361.
32. Sullivan L, Fiellin D: Hepatitis C and HIV infections: implications for clinical care in injection drug users [review]. Am J Addict 2004, 13:1-20.
33. • Weiss J: Adherence to HCV treatment in HCV and HCV/HIV patients. Abstract from National Institutes of Health Computer Retrieval of Information of Scientific Projects (CRISP) database. Available at http://crisp.cit.nih.gov/. Accessed March 2007. Current 5-year study funded by the National Institute of Mental Health to evaluate whether depression, neurocognitive functioning, substance abuse, and treatment self-efficacy are associated with early discontinuation of HCV treatment in patients with HCV and HIV/HCV coinfection.
34. Hewitt R, Roberts J, Shelton M, et al.: High self-esteem, low levels of negative emotionality and few maladaptive beliefs about oneself and one's world predict achievement of undetectable HIV viral load in HIV+ patients receiving antiretroviral therapy [abstract]. Presented at the 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, July 2001, Abstract 705.
35. Conrad S, Garrett L, Cooksley W, et al.: Living with chronic hepatitis C means 'you just haven't got a normal life any more'. Chronic Illn 2006, 2:121-131.
36. Golden J, Conroy R, O'Dwyer A, et al.: Illness-related stigma, mood and adjustment to illness in persons with hepatitis C. Soc Sci Med 2006, 63:3188-3198.
37. Zickmund S, Bryce C, Blasiole J, et al.: Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment. Eur J Gastroenterol Hepatol 2006, 18:381-388.
38. Zickmund S, Ho EY, Masuda M, et al.: "They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med 2003, 18:835-844.
39. Grundy G, Beeching N: Understanding social stigma in women with hepatitis C. Nurs Stand 2004, 19:35-39.
40. Williams A, Burgess J, Danvers K, et al.: Kitchen table wisdom: a Freirian approach to medication adherence. J Assoc Nurses AIDS Care 2005, 16:3-12.
41. Altice F, Mostashari F, Friedland G: Trust and acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 28:47-58.
42. Blasiole J, Shinkunas L, Labrecque D, et al.: Mental and physical symptoms associated with lower social support for patients with hepatitis C. World J Gastroenterol 2006, 12:4665-4672.
43. Forton D, Taylor-Robinson S, Thomas H.: Central nervous system changes in hepatitis C virus infection. Eur J Gastroenterol Hepatol 2006, 18:333-338.
44. Hilsabeck R, Castellon S, Hinkin C: Neuropsychological aspects of coinfection with HIV and hepatitis C virus. Clin Infect Dis 2005, 1:S38-S44.
45. Guadagnino V, Trotta M, Carioti J, et al.: Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users? Dig Liver Dis 2006, 38:119-124.
46. McNally S, Temple-Smith M, Sievert W, et al.: Now, later or never? Challenges associated with hepatitis C treatment. Aust N Z J Public Health 2006, 30:422-427.
47. • Raptopoulou M, Tsantoulas D, Vafiadi I, et al.: The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naïve and nonresponder chronic hepatitis C patients. J Viral Hepat 2005, 12:91-95. Retrospective data analysis of two clinical drug trials in Greece to determine criteria of medication adherence and impact on virologie response to HCV therapy. This study confirmed previous data reported by McHutchison et al. [1•] on adherence rates of greater than 80%.
48. Davis GL, Wong JB, McHutchison JG, et al.: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645-652.
49. Bain VG, Lee SS, Peltekian K, et al.: Exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection: analysis of the Canadian Pegasys Expanded Access program [poster]. Presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; October 27-31, 2006.
50. Reddy KR, Shiffman ML, Morgan TR, et al.: Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa 2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007, 5:124-129.
51. Ferenci P, Fried MW, Shiffman ML, et al.: Predicting sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005, 43:425-433.
52. Schneider J, Kaplan S, Greenfield S, et al.: Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection. J Gen Intern Med 2004, 19:1096-1103.
53. Bakken S, Holzemer W, Brown M, et al.: Relationships between perception of engagement with health care provider and demographic characteristics, health status, and adherence to therapeutic regimen in persons with HIV/AIDS. AIDS Patient Care STDS 2000, 14:189-197.
54. Hamilton H, Gordon C, Nelson M, et al.: Physicians, nonphysician healthcare providers, and patients communicating in hepatitis C: an in-office sociolinguistic study. Gastroenterol Nurs 2006, 29:364-370.
55. Lucas G, Chaisson R, Moore R: Highly active antiretroviral therapy in a large urban clinic: risk factors for virologie failure and adverse drug reactions. Ann Intern Med 1999, 131:81-87.
56. Willenbring M: Integrating care for patients with infectious, psychiatric, and substance use disorders: concepts and approaches. AIDS 2005, 19:S227-S237.
57. Sulkowski M, Thomas D: Hepatitis C in the HIV-infected patient. Clin Liver Dis 2003, 7:179-194.
58. Bica I, McGovern B, Dhar R, et al.: Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001, 32:492-497.
59. Paterson D, Swindells S, Mohr J, et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infections. Ann Intern Med 2000, 133:21-30.
60. Sethi A, Celentano D, Gange S, et al.: Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003, 37:1112-1118.
61. Clanon K, Mueller J, Harank M: Integrating treatment for hepatitis C virus infection into an HIV clinic. Clin Infect Dis 2005, 40:S362-S366.
62. Fleming C, Craven D, Thornton D, et al.: Hepatitis C and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003, 36:97-100.
63. McGovern B, Fiore J, Wurcel A, et al.: Delivering therapy for hepatitis C virus infection to incarcerated HIV-seropositive patients. Clin Infect Dis 2005, 41: S56-S62.
64. Rauch A, Egger M, Reichen J, et al.: Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-alfa plus ribavirin [letter]. J Acquir Immune Defic Syndr 2005, 38:238-240.
65. Restrepo A, Johnson T, Widjaja D, et al.: The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. J Viral Hepat 2005, 12:86-90.
66. Battaglioli-DeNero A: Strategies for improving patient adherence to therapy and long-term patient outcomes. J Assoc Nurses AIDS Care 2007, 18:S17-S22.
67. •• Simoni J, Pearson C, Pantalone D, et al.: Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr 2006, 1:S23-S35. A meta-analysis of randomized, controlled interventional studies utilizing behavioral interventions to improve rates of adherence to ART. Various intervention strategies were shown to be successful, but the researchers call for more research to determine the most efficacious intervention components.
68. Flamm S, Eshelman A, Lyons M, et al.: Improved medication adherence with cognitive behavioral therapy in patients receiving pegylated interferon alpha 2b (1.5mcg/kg/wk) + ribavirin (800-1400mg/day): results of a prospective, randomized, controlled, multi-center trial [abstract]. Hepatology 2002, 36:311.
69. Mulhall B, Younossi Z: Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol 2005, 39:S23-S27.
70. Patel K, Dev AT: Adherence to antiviral therapy in chronic hepatitis C [review]. Curr Hepat Rep 2004, 3:10-15.